Close menu

December 14th, 2022 | 12:02 CET

Bayer, BioNTech, Auxico Resources: 200% price gain possible?

  • Mining
  • Commodities
  • RareEarths
  • Biotechnology
Photo credits:

With lower than expected inflation in the US, the year-end rally has picked up speed. Could the recession be off after all, or at least short-lived? This would likely boost the stock market in the coming year as well. Today we look at three stocks with potential that benefit from global trends and less from developments in Germany. In the case of Bayer, Bernstein Research has outed itself as a super bull. The global agricultural business should continue to run strong. Auxico Resources is positioning itself as a trader of rare earths and critical raw materials. Revenues are expected to jump significantly in the coming year, and analysts say the stock could triple. BioNTech could finally break out of the sideways trend it has been in since early 2022. The new combination vaccine and the cancer pipeline give hope.

time to read: 3 minutes | Author: Fabian Lorenz

Table of contents:

    Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG
    "[...] China's dominance is one of the reasons why we are so heavily involved in the tungsten market. Here, around 85% of production is in Chinese hands. [...]" Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

    Full interview


    Auxico share about to triple?

    Auxico Resources specializes in trading rare earths and critical commodities. Through partnerships in Africa and South America - often with state-owned enterprises - the Canadian company has secured licenses to access over 4 million metric tons. By its own account, this makes it one of the leading suppliers outside China. The advantage of a trader over traditional mining companies: Capital requirements are significantly lower. After the build-up phase in the current year, the Company expects to generate significant revenues in 2023. "Auxico is positioned to become one of the most important suppliers of critical raw materials and rare earths to the global economy," Auxico CEO Frederick Kozak said at last week's IIF virtual investor conference (view presentation Auxico expects a commission income of CAD 10 million to CAD 18 million in the coming year. Since trading costs are manageable, a high margin should be realistic. The Company is currently valued at CAD 30 million.

    It is therefore not surprising that analysts see significant price potential for 2023. Hallgarten, a research house specializing in commodity companies, sees a price target of CAD 1.48 for the Auxico share. The share is currently trading at CAD 0.42. Thus, there is the potential for a tripling. Among other things, the analysts see an end to the price decline in tin. The high-flyer commodity of recent years has crashed from over USD 50,000 to almost USD 20,000 per ton in 2022. In recent months, however, the price has recovered and is now back on an upward trend at around USD 26,000.

    Fittingly, Auxico has recently secured further volumes of high-grade tin in Colombia through a joint venture. This agreement represents a significant amount of tin and a potentially new sustainable revenue stream for the Company. The goal is to export at least 100 tons of high-grade tin per month, with an average tin content of more than 65%. The launch could take place as early as the end of December 2022.

    Bayer share at EUR 96?

    Bayer's stock is one of the bright spots in the DAX in 2022. However, the EUR 55 mark currently seems to be the limit. But according to Bernstein Research, significantly higher prices are possible in the coming year. Thus, the analysts have renewed their "Outperform" recommendation for the DAX group. In the agricultural business, the Leverkusen-based company would benefit from the fundamentally strong situation in the soybean and corn sectors. As a result, they name a price target for the Bayer share of EUR 96. The stock last saw such a price level in 2018. This makes Bernstein the bull among Bayer analysts. Berenberg and Jefferies still believe that the stock is worth EUR 70. But even this still corresponds to a price potential of over 30%. At Bank of America, the figure is only 10%. For the analysts, the Bayer share is a hold, as prices in the pharmaceuticals sector are unlikely to be raised as much as would be necessary due to high inflation. Accordingly, margins are likely to decline. Therefore, their price target is EUR 58.

    BioNTech: Will the breakout succeed?

    Analysts last commented on BioNTech several weeks ago. However, the share has not let this slow it down. It is currently trading at around EUR 165 and is making a new attempt to break out of the sideways trend that has persisted since the beginning of the year. The chances of a breakout are not bad. On the one hand, the combination vaccine against COVID-19 and influenza developed by BioNTech and US partner Pfizer has been approved by the US Food and Drug Administration (FDA) for the accelerated approval procedure. Prior to this, the Phase 1 trial has already begun. This study will investigate the safety, tolerability and immunogenicity of the combined influenza-COVID-19 vaccine candidate in healthy adults. And then, of course, the Mainz-based company is also working through its cancer pipeline. There should be a strong newsflow there in the coming year. The pipeline currently includes 19 product candidates in 24 ongoing clinical trials. For 2023, BioNTech has announced new data from up to 10 clinical trials.

    For Bayer, BioNTech and Auxico Resources, there is a strong case for rising share prices. At Bayer, the glyphosate problem is currently being ignored, and hopes are pinned on a strong agricultural business. If BioNTech continues to shine with positive study results, the share price should also shine again. And then there are also rumors that the COVID-19 vaccine could be used in China after all. Auxico Resources could become one of the surprise stocks of the coming year. The trader has a low capital requirement and higher commodity prices - especially if a global recession fails to materialize - drive profits disproportionately.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on February 2nd, 2023 | 08:00 CET

    Copper on the rise: Kodiak Copper, BASF and JinkoSolar benefit

    • Mining
    • Copper
    • renewableenergies

    Global copper demand is estimated to double by 2035, requiring new mines, mine expansions and technological improvements at existing mines to boost production. One beneficiary of this boom is Kodiak Copper. Assay results from the recently completed drilling in late 2022 have increased the known mineralized envelope at both the Gate & Prime Zone discoveries at its British Columbia project. At the 6th International Investment Forum on February 15, CEO Claudia Tornquist will share more about this with interested investors. BASF is also taking steps to bridge the looming copper shortages due to high demand. A new cooperation is expected to accelerate copper mining. JinkoSolar, on the other hand, as a user of the highly sought-after metal, has struck another new deal. Hedge fund managers are excited.


    Commented by Stefan Feulner on February 1st, 2023 | 20:29 CET

    BioNTech, Defence Therapeutics, PAION - All dams broken

    • Biotechnology

    High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.


    Commented by Stefan Feulner on February 1st, 2023 | 18:17 CET

    Rheinmetall, Defense Metals, Lynas - Time is running out!

    • Mining
    • Tungsten
    • RareEarths
    • Defense

    Heavy weapons for peace. Tanks, submarines and fighter jets for Ukraine, whatever the cost. This scenario is the bitter reality right now and is being promoted across the board by Western politicians. It may not sound very understandable, but in order to guarantee peace, the world continues to arm itself. Companies in the armaments industry, now declared to be sustainable investment opportunities, are booming. With the seething conflict in Taiwan, tensions are again on the rise. With its raw materials, such as rare earth metals, China has the power to act. The West is frantically trying to reduce dependencies, which is impossible to achieve in the short term.